Akari Therapeutics, Plc Restricted Cash
Akari Therapeutics, Plc (AKTX) had Restricted Cash of $60.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCash · last filed 2026-08-13
- 2026-06-30: Restricted Cash $60.00K.
- 2026-03-31: Restricted Cash $60.00K.
- 2025-12-31: Restricted Cash $60.00K.
- 2025-09-30: Restricted Cash $60.00K.
| Period end | Restricted Cash | Restricted Cash as first filed |
|---|---|---|
| 2026-06-30 | $60.00K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $60.00K 10-Q · filed 2026-05-19 | |
| 2025-12-31 | $60.00K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $60.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $60.00K 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $60.00K 10-Q · filed 2026-05-19 | |
| 2024-12-31 | $60.00K 10-K · filed 2026-03-30 | |
| 2024-06-30 | $60.00K 8-K · filed 2024-09-06 | |
| 2023-12-31 | $0.00 10-K · filed 2025-04-15 | $60.00K 8-K · filed 2024-09-06 |
| 2023-06-30 | $60.00K 8-K · filed 2024-09-06 | |
| 2022-12-31 | $239.70K 8-K · filed 2024-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |